124276-71-7

Usage

Uses

Used in Organic Synthesis:
1-(3-methylphenyl)cyclopropane-1-carbonitrile is utilized as a building block in the preparation of various pharmaceutical and agrochemical products. Its unique structure and functional groups make it a valuable component in the synthesis of a wide range of compounds with potential applications in these industries.
Used in Precursor Chemistry:
1-(3-methylphenyl)cyclopropane-1-carbonitrile also serves as a precursor in the production of other complex organic compounds. Its role as a starting material allows for the creation of more intricate molecules with specific properties and functions, contributing to the advancement of chemical research and development.
Used in Pharmaceutical Industry:
1-(3-methylphenyl)cyclopropane-1-carbonitrile is used as a key intermediate in the synthesis of pharmaceuticals, where its unique structure can be leveraged to develop new drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(3-methylphenyl)cyclopropane-1-carbonitrile is employed as a starting material for the development of new pesticides, herbicides, and other agricultural chemicals, aiming to enhance crop protection and yield.
Safety Precautions:
As with all chemical compounds, 1-(3-methylphenyl)cyclopropane-1-carbonitrile should be handled and used with care, adhering to all necessary safety precautions and regulations to ensure the safety of both the users and the environment.

Upstream product

• 1529-41-5 3-chloro-benzeneacetonitrile 
• 107-04-0 1-Bromo-2-chloroethane 
• 2947-60-6 3-methylbenzyl cyanide 
• 106-93-4 ethylene dibromide 

Downstream Products

• 886366-16-1 1-(3-methylphenyl)-1-cyclopropanecarboxylic acid 
• 886366-44-5 (1-(m-tolyl)cyclopropyl)methanol 

Relevant academic research and scientific papers

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Rhodium-Catalyzed Enantioselective Silylation of Cyclopropyl C?H Bonds

Hydrosilyl ethers, generated in situ by the dehydrogenative silylation of cyclopropylmethanols with diethylsilane, undergo asymmetric, intramolecular silylation of cyclopropyl C?H bonds in high yields and with high enantiomeric excesses in the presence of

PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

N-BENZYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), and inhibit kinase-mediated (e.g., cdk5-mediated) phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. Side effects such as significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, can be avoided in the mammal receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.